Priority review for AZ’ hairy cell leukaemia drug
US regulators have assigned priority review status to AstraZeneca and MedImmune’s moxetumomab pasudotox, which is being developed as a treatment for hairy cell leukaemia (HCL).
Read More
Tag: moxetumomab pasudotox
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
